

Comparison of Saliva sample and Nasopharyngeal Sample for the Diagnosis of COVID 19 in a Single Center in Bangladesh

Md. Saiful Islam¹, Arifa Akram², Md Abdullah Yusuf³, Shahin Mahmud⁴

¹Associate Professor, Department of Microbiology, National Institute of Laboratory Medicine and Referral Center, Dhaka, Bangladesh; ²Arifa Akram Assistant Professor, Department of Virology, National Institute of Laboratory Medicine and Referral Center, Dhaka, Bangladesh; ³Associate Professor, Department of Microbiology, National Institute of Neurosciences & Hospital, Dhaka, Bangladesh; ⁴Medical officer, National Institute of Neurosciences & Hospital, Dhaka, Bangladesh

[Received: 12 January 2022; Accepted: 3 March 2022; Published: 1 April 2022]

Abstract

Background: As rapid and precise detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patient but there are limited data comparing sensitivity of saliva and nasopharyngeal swab (NPS) specimen for SARS-CoV-2 detection. Saliva is less invasive and more convenient for the patients. But NPS is the reference sampling method for the detection of SARS-Cov-2. **Objective:** It was aimed to compare the sensitivity specificity of nasopharyngeal saliva and saliva swab compared to for COVID-19 testing. **Methodology:** This cross-sectional study was conducted from 15 April to 30 April, 2021. One saliva sample and another NPS sample collected from 100 peoples and amplified using three different target genes (RdRP, N and E genes) by RT-PCR. Sensitivity, specificity and positive and negative predictive values of Saliva swab was determined using NPS swab RT-PCR as the gold standard for diagnosis of COVID 19. **Results:** Among 100 people, 58 were men. The median age was 31 years. Among total patients most common symptoms were fever followed by sore throat and cough. The sensitivity and specificity of saliva samples were 91% and 100% respectively. Positive predictive value and negative predictive value were 100% and 88% respectively. An analysis of the agreement between the two specimens revealed 89% observed agreement (k coefficient 0.89, $p < 0.001$). **Conclusions:** Saliva can be an alternative sampling method in patients who cannot provide a NPS sample for the diagnosis of COVID-19. As this method is non-invasive, and non-aerosol generating, it can provide a good diagnostic performance. [*Bangladesh Journal of Infectious Diseases, April 2022;9(suppl_1):S20-S23*]

Keywords: SARS CoV-2; COVID-19; RT-PCR; Nasopharyngeal swabs; Saliva

Correspondence: Dr Arifa Akram, Assistant Professor and Lab head, Department of Virology, National Institute of Laboratory Medicine and Referral Center, Dhaka, Bangladesh; Email: drbarna43@gmail.com; Cell No.: +8801816296249; ORCID ID: <https://orcid.org/0000-0001-8829-9817>

Conflict of interest: The author(s) declared no potential conflicts of interest.

Funding agency: This study was supported by Seegene (Korea) that provides kit donation to NILMRC.

Contribution to authors: SI contributed to conception and design, data analysis, and drafted the manuscript. AA contributed to collect and process the samples. AY and SM contributed to data interpretation and critically revised the manuscript. All authors gave final approval and agree to be accountable for all aspects of the work.

How to cite this article: Islam MS, Akram A, Yusuf MA, Mahmud S. Comparison of Saliva sample and Nasopharyngeal Sample for the Diagnosis of COVID 19 in a Single Center in Bangladesh. *Bangladesh J Infect Dis* 2022;9(suppl_1):S20-S23

Copyright: ©2022. Islam et al. Published by Bangladesh Journal of Infectious Diseases. This article is published under the Creative Commons CC BY-NC License (<https://creativecommons.org/licenses/by-nc/4.0/>). This license permits use, distribution and reproduction in any medium, provided the original work is properly cited, and is not used for commercial purposes.

Introduction

The emergence of SARS CoV-2 from Hubei Province of China spread to other parts of the world after its discovery on December 2019¹. The virus poses great threat to global public health and caused remarkable losses economically².

Rapid and obviously accurate detection of 2019-nCoV is essential for controlling the outbreak³. COVID-19 is primarily diagnosed via reverse transcription-polymerase chain reaction (RT-PCR). In most of the countries, nasopharyngeal (NPS) swab and throat swab (TS) are the principal means for collecting specimens for testing. But collection procedure for NPS and TS cause not only discomfort but also require trained healthcare staff to perform. Saliva and self-administered nasal (SN) swabs are, in many ways, ideal specimens for COVID-19 screening as these can be collected without trained staff. A meta-analysis suggests that saliva is at best slightly less sensitive or similar to other specimens, including NP swabs³.

SARS-CoV-2 genome is closely related to that of SARS-CoV⁴. SARS-CoV and SARS-CoV-2 both attach with host cell angiotensin-converting enzyme 2 for cellular entry⁵. In a previous study it is showed a higher level of angiotensin-converting enzyme 2 expressions in salivary glands in SARS CoV patients⁶. So saliva droplets can play role in viral transmission⁷. These studies suggested that the salivary glands could be a probable target for SARS-CoV-2 infection, and hence saliva could be a potential sample for the detection of SARS-CoV-2¹.

Based on the previous studies, it was compared the RT-PCR test performance of the saliva sample with NPS samples in 100 people. For all RT-PCR tests, we used the commercial Allplex™ 2019-nCoV Assay Kit (Seegene, Korea), which was previously validated for clinical diagnosis with NPS, oropharyngeal swabs (OPS), sputum, and bronchoalveolar lavage (BAL).

Methodology

Study Population: This cross-sectional study was conducted from 15 April to 30 April 2021. Paired samples were collected, one saliva sample and another NPS sample, from people. The inclusion criteria were those who presented with a history of fever or acute respiratory symptoms or who had a history of contact with an individual who was confirmed to have or suspected of having COVID-19. Individuals aged more than 18 years old were

excluded. The study was approved by the NILMRC Ethics Committee.

Specimen Collection: Nasopharyngeal swab specimens were collected by medical technologists in viral transport medium and then transported to our lab with precaution. For collection of saliva samples, an assisted self-sampling was done. Patients were advised to collect saliva by tilting their head backwards for 10 seconds and then spit it into a sterile vial. A total of 1–5 mL of saliva was collected in a sterile, leak-proof screw cap container. No preservative is required. Both the samples were collected according to the standard operating procedure of the CDC in the United States⁸.

RNA Extraction and RT PCR: Prior to RNA extraction, proteinase k was added to the saliva samples and incubated at 56°C by 10 min⁹. RNA extraction and amplification of all samples was performed using the STARmag kit (Seegene, Korea) according to manufacturer's instructions. RT PCR amplification in the QuantStudio™ 5 Dx Real-Time PCR. The Allplex™ 2019-nCoV Assay Kit targeted 3 genes (N, RdRP, and E). When the internal control was not amplified, it was considered as indeterminate. It is currently considered as positive if both the N gene and RdRP were amplified.

Statistical Analysis: SPSS software, version 19 (SPSS Inc., Chicago, IL, USA) was used to analyze the data. Categorical variables were summarized as frequencies and percentages. Reported p-values of <0.05 were considered statistically significant. Sensitivity, specificity and positive and negative predictive values of saliva was determined using NPS swab RT PCR as the gold standard for diagnosis of COVID 19. The relative sensitivity and specificity of the tests were determined as follows (TP is True Positive, TN represents True Negative, FN is False negative and FP is False Positive). Sensitivity = $TP / (TP + FN) \times 100$; Specificity = $TN / (TN + FP) \times 100$, Positive predictive value = $TP / (TP + FP) \times 100$, Negative predictive value = $TN / (TN + FN) \times 100$. The degree of agreement between two tests was determined by Cohen kappa coefficient (κ) values with 95% confidence intervals and expressed as k value. Kappa values express the agreement between two tests i.e. NPS and Saliva RT PCR result. K value interpreted as follows <0.20 = poor, 0.21-0.40 = fair, 0.41-0.60 = moderate, 0.61-0.80 = good and 0.81-1.00 = indicates a very good agreement¹⁰.

Results

A total of 100 patients were included in this study. The mean age was 31 years. Among total patients most common symptoms were fever followed by sore throat and cough (Table 1).

Table 1: Demographics Characteristics of Study Population

Characteristics	n=100
Age groups	
• Mean (SD)	31.2 (14.19)
Symptoms	
• Fever	80
• Cough	65
• Sore throat	72
• Runny nose	43
• Respiratory difficulties	10
• Anosmia	22
• Ageusia	17
• Diarrhoea	30

Both nasopharyngeal and saliva samples were collected from them. 58 individuals were men (Figure I).




Figure I: Gender Distribution of Study Population

RT-PCR results of the nasopharyngeal swab was used as the reference standard to determine the diagnostic test performance of RT-PCR of the saliva. An analysis of the agreement between the two specimens revealed a 89% observed agreement (k coefficient 0.89, $p < 0.001$). (Table 2).

Table 2: Comparison for the Detection of SARS-CoV-2 RT-PCR between Nasopharyngeal and Throat Swab and Saliva Sample

Saliva Samples	Nasopharyngeal samples		Total	P value	Kappa value
	Positive	Negative			
Positive	55	0	55	<0.001	0.89
Negative	5	40	45		

The sensitivity and specificity of saliva samples were 91% and 100% respectively. Positive predictive value and negative predictive value were 100% and 88% respectively.

Table 3: Diagnostic Validity of Saliva sample for SARS CoV2 detection

Validity	Values
Sensitivity	91.0%
Specificity	100.0%
PPV	100.0%
NPV	88.0%

The median Ct values of the ORF1ab and N genes were 32.7 (22.5-34.0) and 31.8 (25-33),

respectively in saliva specimens, and 32.0 (27.4-34.3) and 30.5 (26.1-32.3), respectively, in nasopharyngeal and throat swabs (Table 3).

Discussion

In this study, it has shown that saliva samples can be used as a non-invasive method for the detection of SARS-CoV-2. The saliva RT PCR test demonstrated good sensitivity and comparable performance to the current standard of nasopharyngeal swab. The k coefficient value showed a very good agreement of the diagnosis between the standard nasopharyngeal and throat swab and the saliva sample.

In case of asymptomatic patients, to find a safe and reliable diagnostic specimen for detection of SARS CoV-2 is essential. Already it has been detected in saliva, nasopharyngeal or throat swabs, blood, feces, urine, and tears, among which nasopharyngeal swab and saliva are more commonly used for the detection of COVID-19¹¹.

But these specimens collection cause not only discomfort to the patients and but also put health-care workers at risk for disease transmission¹². So, our study aimed to detect SARS CoV-2 from saliva samples.

So it has found many advantages of saliva sample like non invasive, less chance of nosocomial 2019-nCoV transmission and finally collection of sample can be done outside the hospitals, such as in outpatient clinics or in the community. In school, college or any office where a large number of individuals require screening, saliva can be a better alternative. Last not least since healthcare workers are not required to collect saliva specimens, it will eliminate the waiting time for specimen collection, and hence the results would be available much sooner. This is especially important in case of limited staff¹².

In this study, both swabs can detect 55 positives and 40 negative specimens equally. But saliva specimens failed to detect 5 samples; the reason may be a lower viral load or may be processing error. Previous studies reported that the sensitivity of the SARS CoV-2 detection by RT-RT PCR in saliva samples was 69.2% to 100.0%¹³.

However, in this study, it has included positive and negative samples for SARS-Cov2 and all samples are collected in the same patient and at the same time and we found good sensitivity and specificity in our study.

There are some limitations. Saliva samples cannot be given by pediatric age group or hospitalized or ICU patients. And if presenting symptoms is dry cough then saliva collection will be also difficult¹⁴.

Conclusion

In conclusion, this study proved that saliva as a sensitive and less invasive sample for COVID-19 diagnosis. It can be an alternative sampling method in patients who cannot provide a NPS sample for the diagnosis of COVID-19.

Acknowledgments: The authors are grateful to medical technologists of NILMRC and all staffs who are related to COVID 19 sample collection and data entry.

References

1. Pasomsab E, Watcharananan SP, Boonyawat K, Janchompoo P, Wongtabtim G, Suksuwan W, et al. Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease 2019: a cross-sectional study. *Clinical Microbiology and Infection*. 2021;27(2):285-e1
2. Akram A, Molla MM, Yeasmin M, Nafisa T, Monir MB, Islam J, et al. Knowledge, attitude and practices toward COVID-19 among healthcare workers in National Institute of Laboratory Medicine and Referral Center, Dhaka, Bangladesh. *Microbes and Infectious Diseases*. 2021;2(3):433-9.
3. Teo AK, Choudhury Y, Tan IB, Cher CY, Chew SH, Wan ZY, et al. Saliva is more sensitive than nasopharyngeal or nasal swabs for diagnosis of asymptomatic and mild COVID-19 infection. *Scientific reports*. 2021;11(1):1-8.
4. Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. *Sci China Life Sci* 2020;63:457e60.
5. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell* 2020;181:271e80.
6. Xu J, Li Y, Gan F, Du Y, Yao Y. Salivary glands: potential reservoirs for COVID-19 asymptomatic infection. *Journal of dental research*. 2020;99(8):989-.
7. Liu L, Wei Q, Alvarez X, Wang H, Du Y, Zhu H, et al. Epithelial cells lining salivary gland ducts are early target cells of severe acute respiratory syndrome coronavirus infection in the upper respiratory tracts of rhesus macaques. *Journal of virology*. 2011;85(8):4025-30.
8. CDC. Covid 19: Interim Guidelines for Collecting and Handling of Clinical Specimens for COVID-19 Testing. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html>
9. Chu AW, Chan WM, Ip JD, Yip CC, Chan JF, Yuen KY, To KK. Evaluation of simple nucleic acid extraction methods for the detection of SARS-CoV-2 in nasopharyngeal and saliva specimens during global shortage of extraction kits. *Journal of Clinical Virology*. 2020;129:104519.
10. Altman DG (1991). *Practical statistics for medical research*. London: Chapman and Hall. Available at <https://www.medcalc.org/manual/kappa.php>. [Accessed on July 25, 2018].
11. Nasiri K, Dimitrova A. Comparing saliva and nasopharyngeal swab specimens in the detection of COVID-19: A systematic review and meta-analysis. *Journal of Dental Sciences*. 2021;16(3):799-805.
12. To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *Lancet Infect Dis* 2020
13. Tapia CV, Marcia C, Ivone M, Nadia P, Lesly M, Camila G, et al. Performance of Saliva Samples for COVID-19 Diagnosis by Using the Allplex™ 2019-nCoV Assay Kit. *Front. Med*. 2021;8:617399
14. Chen Q, Zheng Z, Zhang C, Zhang X, Wu H, Wang J, et al. Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19) in Taizhou, Zhejiang, China. *Infection*. 2020;48(4):543-51